



Figure S1. ArCC treatment did not cause reduction of viability at 10–1000 µg/mL in Stimulated Human Umbilical Vascular Endothelial Cells (HUVECs). The effect of the ArCC on HUVEC viability was determined using a bioluminescent assay and compared after 24, 48, and 72 h of treatment at the indicated concentrations in the presence of 15 ng/mL Tumor Necrosis Factor- α (TNF- α). Data are presented as means \pm SEM ($n = 3$). Similar results were observed in replicate experiments.